St. Jude Builds Chronic Pain Business With NeuroTherm Acquisition
This article was originally published in The Gray Sheet
NeuroTherm makes devices for radiofrequency ablation of nerves in painful facet joints in the neck or back to treat chronic pain. Although it markets neurostimulators, St. Jude currently does not sell any devices in the radio-frequency ablation segment of the pain-therapy market.
You may also be interested in...
The warning letter highlights validation and recordkeeping problems at the Atlanta manufacturing facility for the CardioMEMS heart failure remote monitoring system, but it is not expected to affect device availability.
In March, St. Jude Medica received CE mark for its Prodigy Chronic Pain System with Burst Technology. According to the company, Prodigy is the only spinal cord stimulation device on the market that offers both tonic and burst stimulation to patients suffering from chronic pain.
Neuromodulation is one of the largest and fastest growing segments of the worldwide medical device market, with global revenues expected to reach $6 billion by 2020; as a result, the number of products in the neuromodulation pipeline is exploding. New and improved technologies will permit deeper penetration of neuromodulation therapies into existing patient groups as well as expansion of the market to new patient populations that could eventually number in the multi-millions.